间质性膀胱炎/膀胱疼痛综合征的保守治疗

高志明; 魏大东; 夏海波

doi:10.13201/j.issn.1001-1420.2015.10.026

间质性膀胱炎/膀胱疼痛综合征的保守治疗

- 赤峰学院附属医院(新城)泌尿外科(内蒙古赤峰, 024000)

详细信息

通讯作者: 夏海波,E-mail:15998672050@163.com

中图分类号: R694.3

收稿日期: 2014-11-04

Conservative treatment of interstitial cystitis/bladder pain syndrome

- Department of Urology, Affiliated Hospital of Chifeng University, Chifeng, Inner Mongolia, 024000, China

More Information

Corresponding author: XIA Haibo, E-mail: 15998672050@163.com

Received Date: 04 November 2014

摘要

摘要: 间质性膀胱炎(IC)/膀胱疼痛综合征(BPS)的治疗较为困难且疗效不佳。目前尚无明确病因和有效治疗方法。美国泌尿外科协会(AUA)出版了关于IC/BPS的诊疗指南,一线治疗包括:健康教育,自我护理,行为矫正,缓解压力和学习积极的应对技巧^〔1〕。患者和医师把IC/BPS当成慢性病对待,将会获得更为满意的结果。本文就IC/BPS的保守治疗和将IC/BPS视为慢性病治疗的益处做一综述。
- 间质性膀胱炎 /
- 保守治疗 /
- 慢性病
Abstract: The management of interstitial cystitis/bladder pain syndrome (IC/BPS) is both frustrating and difficult. The etiology is uncertain and there is no definitive treatment. The American Urological Association (AUA) provides a guideline for the diagnosis and treatment of IC/BPS. Recommended first-line treatments include patient education, self-care practices, behavior modifications, stress management, and positive coping techniques^〔1〕. Management of IC/BPS may be also improved if we treat this condition as a chronic disease. This article reviews the AUA first-line treatments for IC/BPS and the benefits of treating this condition as a chronic disease.
- interstitial cystitis /
- conservative treatment /
- chronic disease

HTML全文

参考文献(36)

[1]	Hanno P M, Burks D A, Clemens J Q, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome[J]. J Urol, 2011, 185(6):2162-2170.
[2]	朱绪辉, 杜鹏, 善辉, 等. 阿米替林联合透明质酸钠治疗膀胱疼痛综合征/间质性膀胱炎的临床研究(附58例报告)[J]. 临床泌尿外科杂志, 2012, 27(2):117-120, 123.
[3]	Nickel J C, Tripp D A, Pontari M, et al. Psychosocial phenotyping in women with interstitial cystitis/painful bladder syndrome:a case control study[J]. J Urol, 2010, 183(1):167-172.
[4]	Lai H H. Clinical trials:Placebo effects in interstitial cystitis/bladder pain syndrome[J]. Nat Rev Urol, 2014, 11(9):494-495.
[5]	Gülpınar O, KayışA, Süer E, et al. Clinical comparision of intravesical hyaluronic acid and hyaluronic acid-chondroitin sulphate therapy for patients with bladder pain syndrome/interstitital cystitis[J]. Can Urol Assoc J, 2014, 8(9-10):E610-E614.
[6]	Robinson R, Montejano L, Ruiz K, et al. The economic burden of interstitial cystitis and painful bladder syndrome[J]. J Urol, 2011, 185(4 Suppl):e129.
[7]	Fiehn O, Kim J. Metabolomics insights into pathophysiological mechanisms of interstitial cystitis[J]. Int Neurourol J, 2014, 18(3):106-114.
[8]	Diniz S, Dinis P, Cruz F, et al. Bladder pain syndrome/interstitial cystitis:present and future treatment perspectives[J]. Minerva Urol Nefrol, 2013, 65(4):263-276.
[9]	Fall M, Peeker R. Methods and incentives for the early diagnosis of bladder pain syndrome/interstitial cystitis[J]. Expert Opin Med Diagn, 2013, 7(1):17-24.
[10]	Vas L, Pattanik M, Titarmore V. Treatment of interstitial cystitis/painful bladder syndrome as a neuropathic pain condition[J]. Indian J Urol, 2014, 30(3):350-353.
[11]	Tirlapur S A, Riordain R N, Khan K S, et al. Variations in the reporting of outcomes used in systematic reviews of treatment effectiveness research in bladder pain syndrome[J]. Eur J Obstet Gynecol Reprod Biol, 2014, 180:61-67.
[12]	Rourke W, Khan S A, Ahmed K, et al. Painful bladder syndrome/interstitial cystitis:aetiology, evaluation and management[J]. Arch Ital Urol Androl, 2014, 86(2):126-131.
[13]	Van der Aa F, Beckley I, de Ridder D. Polyomavirus BK——a potential new therapeutic target for painful bladder syndrome/interstitial cystitis[J]? Med Hypotheses, 2014, 83(3):317-320.
[14]	Fall M, Oberpenning F, Peeker R. Treatment of bladder pain syndrome/interstitial cystitis 2008:can we make evidence-based decisions[J]? Eur Urol, 2008, 54(1):65-75.
[15]	Bosch P C. Examination of the significant placebo effect in the treatment of interstitial cystitis/bladder pain syndrome[J]. Urology, 2014, 84(2):321-326.
[16]	Schrepf A, O'Donnell M, Luo Y, et al. Inflammation and inflammatory control in interstitial cystitis/bladder pain syndrome:Associations with painful symptoms[J]. Pain, 2014, 155(9):1755-1761.
[17]	Shorter B, Lesser M, Moldwin R M, et al. Effect of comestibles on symptoms of interstitial cystitis[J]. J Urol, 2007, 178(1):145-152.
[18]	Carrico D J, Peters K M, Diokno A C. Guided imagery for women with interstitial cystitis:results of a prospective, randomized controlled pilot study[J]. J Altern Complement Med, 2008, 14(1):53-60.
[19]	Gülpınar O, Haliloğlu A H, G kce M İ, et al. Instillation of Hyaluronic Acid via Electromotive Drug Administration Can Improve the Efficacy of Treatment in Patients With Interstitial Cystitis/Painful Bladder Syndrome:A Randomized Prospective Study[J]. Korean J Urol, 2014, 55(5):354-359.
[20]	Chelimsky T, Chelimsky G, McCabe N P, et al. Interstitial Cystitis-Elucidation of Psychophysiologic and Autonomic Characteristics (the ICEPAC Study):design and methods[J]. J Pain Res, 2014, 7:243-253.
[21]	Fiehn O, Kim J. Metabolomics insights into pathophysiological mechanisms of interstitial cystitis[J]. Int Neurourol J, 2014, 18(3):106-114.
[22]	Nickel J C, Tripp D A, Pontari M, et al. Psychosocial phenotyping in women with interstitial cystitis/painful bladder syndrome:a case control study[J]. J Urol, 2010, 183(1):167-172.
[23]	Tsai C F, Ouyang W C, Tsai S J, et al. Risk factors for poor sleep quality among patients with interstitial cystitis in Taiwan[J]. Neurourol Urodyn, 2010, 29(4):568-572.
[24]	王超, 廖泽明, 蔡勇. 中西医结合治疗膀胱疼痛综合征/间质性膀胱炎24例报告[J]. 临床泌尿外科杂志, 2013, 28(7):550-551.
[25]	Kim J, Freeman M R. Antiproliferative factor signaling and interstitial cystitis/painful bladder syndrome[J]. Int Neurourol J, 2011, 15(4):184-191.
[26]	Check J H, Cohen G, Cohen R, et al. Sympathomimetic amines effectively control pain for interstitial cystitis that had not responded to other therapies[J]. Clin Exp Obstet Gynecol, 2013, 40(2):227-228.
[27]	Beckett M K, Elliott M N, Clemens J Q, et al. Consequences of interstitial cystitis/bladder pain symptoms on women's work participation and income:resultsfrom a national household sample[J]. J Urol, 2014, 191(1):83-88.
[28]	Colaco M A, Evans R J. Current recommendations for bladder instillation therapy in the treatment of interstitial cystitis/bladder pain syndrome[J]. Curr Urol Rep, 2013, 14(5):442-447.
[29]	Neuhaus J, Schwalenberg T. Intravesical treatments of bladder pain syndrome/interstitial cystitis[J]. Nat Rev Urol, 2012, 9(12):707-720.
[30]	Nordling J, Fall M, Hanno P. Global concepts of bladder pain syndrome (interstitial cystitis)[J]. World J Urol, 2012, 30(4):457-464.
[31]	Takahashi S. Editorial comment to on-and post-treatment symptom relief by repeated instillations of heparin and alkalizedlidocaine in interstitial cystitis[J]. Int J Urol, 2013, 20(11):1123.
[32]	Argade S, Shaw T, Su Y, et al. Tamm-Horsfall protein-associated nucleotides in patients with interstitial cystitis[J]. BJU Int, 2013, 111(5):811-819.
[33]	Pinto R, Lopes T, Silva J, et al. Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractorybladder pain syndrome/interstitial cystitis[J]. J Urol, 2013, 189(2):548-553.
[34]	Schmidt C W. Questions persist:environmental factors in autoimmune disease. Environ Health Perspect[J]. 2011, 119(6):A249-A253.
[35]	Javierre B M, Hernando H, Ballestar E. Environmental triggers and epigenetic deregulation in autoimmune disease[J]. Discov Med, 2011, 12(67):535-545.
[36]	Yamada T. Significance of complications of allergic diseases in young patients with interstitial cystitis[J]. Int J Urol, 2003, 10 Suppl:S56-S58.